HUP0500791A2 - Controlled release formulation of clarithromycin or tinidazol - Google Patents

Controlled release formulation of clarithromycin or tinidazol

Info

Publication number: HUP0500791A2
Authority: HU; Hungary
Prior art keywords: tinidazol; clarithromycin; controlled release; release formulation; formulation
Prior art date: 2001-08-29

Application number

HU0500791A

Other languages

English (en)

Inventor

Ashok Rampal

Rajeev S Raghuvanshi

Manoj Kumar

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-29

Filing date

2002-01-22

Publication date

2006-09-28

2001-08-29 Priority claimed from PCT/IB2001/001564 external-priority patent/WO2002017885A2/en

2002-01-22 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2002-01-22 Priority claimed from PCT/IB2002/000175 external-priority patent/WO2003017981A1/en

2006-09-28 Publication of HUP0500791A2 publication Critical patent/HUP0500791A2/hu

Links

HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 title 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title 1
229960002626 clarithromycin Drugs 0.000 title 1
238000013270 controlled release Methods 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960005053 tinidazole Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU0500791A 2001-08-29 2002-01-22 Controlled release formulation of clarithromycin or tinidazol HUP0500791A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/IB2001/001564 WO2002017885A2 (en)	2000-08-29	2001-08-29	Controlled release formulation of erythromycin or a derivative thereof
PCT/IB2002/000175 WO2003017981A1 (en)	2001-08-29	2002-01-22	Controlled release formulation of clarithromycin or tinidazol

Publications (1)

Publication Number	Publication Date
HUP0500791A2 true HUP0500791A2 (en)	2006-09-28

Family

ID=32259846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0500791A HUP0500791A2 (en)	2001-08-29	2002-01-22	Controlled release formulation of clarithromycin or tinidazol

Country Status (10)

Country	Link
US (1)	US20050053657A1 (hu)
EP (1)	EP1423097A1 (hu)
CN (1)	CN1575164A (hu)
BR (1)	BR0212259A (hu)
CA (1)	CA2458776A1 (hu)
EA (1)	EA200400343A1 (hu)
HU (1)	HUP0500791A2 (hu)
NO (1)	NO20041196L (hu)
PL (1)	PL368306A1 (hu)
ZA (1)	ZA200402007B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
EP1830886B1 (en) *	2004-12-27	2016-04-13	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
EP2283824B1 (en) *	2009-07-30	2017-04-19	Special Products Line S.p.A.	Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
EP2671571A1 (en) *	2012-06-05	2013-12-11	Sanovel Ilac Sanayi ve Ticaret A.S.	Controlled-release formulations of clarithromycin
CN104042585B (zh) *	2014-05-21	2016-08-24	丽珠医药集团股份有限公司	一种替硝唑的口服制剂
CN105310990B (zh) *	2014-12-04	2018-01-19	蚌埠丰原涂山制药有限公司	一种防止粘冲和裂片的对乙酰氨酚片及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4076804A (en) *	1975-07-18	1978-02-28	Abbott Laboratories	Erythromycin therapy
GB1577196A (en) *	1977-06-03	1980-10-22	Ile De France	Compositions containing erythromycin and metoclopramide
US4119723A (en) *	1977-07-08	1978-10-10	John R. A. Simoons	Treatment of rheumatoid arthritis and related diseases
US4331803A (en) *	1980-06-04	1982-05-25	Taisho Pharmaceutical Co., Ltd.	Novel erythromycin compounds
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4571333A (en) *	1983-06-14	1986-02-18	Syntex (U.S.A.) Inc.	Controlled release naproxen and naproxen sodium tablets
US5200193A (en) *	1987-04-22	1993-04-06	Mcneilab, Inc.	Pharmaceutical sustained release matrix and process
US4808411A (en) *	1987-06-05	1989-02-28	Abbott Laboratories	Antibiotic-polymer compositions
US5009897A (en) *	1988-06-24	1991-04-23	Abbott Laboratories	Pharmaceutical granules and tablets made therefrom
US4970081A (en) *	1989-01-03	1990-11-13	Sterling Drug Inc.	Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5518730A (en) *	1992-06-03	1996-05-21	Fuisz Technologies Ltd.	Biodegradable controlled release flash flow melt-spun delivery system
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
US6096339A (en) *	1997-04-04	2000-08-01	Alza Corporation	Dosage form, process of making and using same
US6010718A (en) *	1997-04-11	2000-01-04	Abbott Laboratories	Extended release formulations of erythromycin derivatives
US5869098A (en) *	1997-08-20	1999-02-09	Fuisz Technologies Ltd.	Fast-dissolving comestible units formed under high-speed/high-pressure conditions
IN186245B (hu) *	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US6090411A (en) *	1998-03-09	2000-07-18	Temple University	Monolithic tablet for controlled drug release
WO2003024427A1 (en) *	1999-12-20	2003-03-27	Temple University Of The Commonwealth System Of Higher Education	Tableted oral extended release dosage form

2002
- 2002-01-22 US US10/488,112 patent/US20050053657A1/en not_active Abandoned
- 2002-01-22 CN CNA028213491A patent/CN1575164A/zh active Pending
- 2002-01-22 EA EA200400343A patent/EA200400343A1/ru unknown
- 2002-01-22 CA CA002458776A patent/CA2458776A1/en not_active Abandoned
- 2002-01-22 BR BR0212259-6A patent/BR0212259A/pt not_active IP Right Cessation
- 2002-01-22 PL PL02368306A patent/PL368306A1/xx not_active Application Discontinuation
- 2002-01-22 EP EP02710212A patent/EP1423097A1/en not_active Withdrawn
- 2002-01-22 HU HU0500791A patent/HUP0500791A2/hu unknown
2004
- 2004-03-12 ZA ZA200402007A patent/ZA200402007B/en unknown
- 2004-03-23 NO NO20041196A patent/NO20041196L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20050053657A1 (en)	2005-03-10
CN1575164A (zh)	2005-02-02
BR0212259A (pt)	2004-10-19
ZA200402007B (en)	2004-09-15
NO20041196L (no)	2004-03-23
CA2458776A1 (en)	2003-03-06
EP1423097A1 (en)	2004-06-02
PL368306A1 (en)	2005-03-21
EA200400343A1 (ru)	2004-08-26

Legal Events

Date	Code	Title	Description
2007-06-28	FD9A	Lapse of provisional protection due to non-payment of fees

Publication	Publication Date	Title
IL161996A0 (en)	2005-11-20	Directly compressible formulations of azithromycin
GB0218157D0 (en)	2002-09-11	Compositions for controlled release
GB2376049B (en)	2004-03-03	Controlling activation of devices
IL159048A0 (en)	2004-05-12	Sustained release formulation
PL348575A1 (en)	2002-06-03	Controlled release formulation comprising gnrh-ii
HUP0401017A3 (en)	2005-06-28	Combination of probiotics
EP1581160A4 (en)	2009-08-12	ENCAPSULATION PRODUCTS PROVIDING CONTROLLED OR PROLONGED DELIVERY
AU2001286677A1 (en)	2002-03-04	Controlled release of substances
HUP0302847A3 (en)	2005-05-30	Pharmaceutical formulation comprising bicalutamide
EP1372614A4 (en)	2007-10-31	SULPHONYL UREA FORMULATION WITH CONTROLLED RELEASE
SG84623A1 (en)	2001-11-20	Controlled release compositions
GB0017468D0 (en)	2000-08-30	Silicone release coating compositions
IL161902A0 (en)	2005-11-20	Pharmaceutical formulation comprising bicalutamide
EP1501352A4 (en)	2007-03-07	METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE
HUP0500791A2 (en)	2006-09-28	Controlled release formulation of clarithromycin or tinidazol
HUP0204417A3 (en)	2005-03-29	Oral ciprofloxacin-composition of controlled release
HUP0500734A3 (en)	2005-12-28	Use of 2-alkoxyphenyl-substituted imidazotriazinones
AU2003300543A1 (en)	2004-07-14	Slow release formulation of clarithromycin
AU2002337843A8 (en)	2007-09-20	Processes for the preparation of substituted isoxazoles and 2-isoxazolines
EP1620111A4 (en)	2012-03-21	FORMULATION OF ERYTHROMYCIN DERIVATIVES WITH CONTROLLED RELEASE
IL161178A0 (en)	2004-08-31	MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
GB0125492D0 (en)	2001-12-12	Formulation
AU2002365136A8 (en)	2003-07-30	Compositions and methods for controlled release
GB2375048B (en)	2003-11-19	Formulation
GB2396812B (en)	2005-11-02	Formulation